In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AbbVie, BI settle IP litigation surrounding BI's Cyltezo, a Humira biosimilar

Executive Summary

AbbVie and Boehringer Ingelheim GmbH resolved all ongoing intellectual property litigation regarding BI's Cyltezo (adalimumab-adbm), a biosimilar to AbbVie's Humira (adalimumab). Cyltezo was FDA approved in August 2017 for chronic inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, axial spondyloarthritis, and ulcerative colitis. Per the settlement, BI can start selling Cyltezo in the US on July 1, 2023. In exchange for licensing BI its Humira patents, AbbVie will receive royalties on US sales once Cyltezo is launched. The settlement enables BI to be among the first companies to secure future patient access in the US to a Humira alternative.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies